EUCTR2020-000645-14-GB进行中（未招募）1 期
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) - PERSEUS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 18 to 55 years of age inclusive
- •- Diagnosis of PPMS according to the 2017 McDonald criteria
- •- Expanded disability status scale (EDSS) score between 2.0 to 6.5 points, at screening inclusive
- •- Positive cerebrospinal fluid oligoclonal bands and/or elevated Immunoglobulin G (IgG) index either during screening or documented previous history.
- •- Contraceptive use consistent with local regulations for individuals participating in clinical studies Participant is eligible to participate if she is not pregnant or
- •breastfeeding, and at least one of the following conditions applies:
- •- Is not a woman of child bearing potential (WOCBP)
- •- Is a WOCBP and agrees to use an acceptable contraceptive method
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1320
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Participant has conditions that would adversely affect study participation such as short life expectancy.
- •- History of organ transplant.
- •- Evidence of infection with human immunodeficiency virus (HIV), progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation.
- •- History of malignancy within 5 years prior to screening.
- •- History of alchohol or drug abuse within 1 year prior to Screening.
- •- Hospitalized for psychiatric disease within 2 years prior to Screening.
- •- Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening.
- •- Bleeding disorder, known platelet dysfunction or platelet count <150 000/µL at Screening or history of significant bleeding event within 6 months prior to Screening.
- •- Lymphocyte count below the lower limit of normal at Screening.
- •- Recent live (attenuated) vaccine within 2 months before the first treatment visit.
- •- Recent major surgery (within 4 weeks of Screening) or planned major surgery during the study.
- •- The participant has received medications/treatments for MS within a specified time frame.
- •- Receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes.
- •- Receiving anticoagulant or antiplatelet therapy (such as aspirin, clopidogrel, warfarin).
- •- Contraindications to magnetic resonance imaging (MRI).
- •NOTE: Other Inclusion/Exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-PTGenzyme Corporation1,700
进行中（未招募）
1 期
Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor SAR442168 (PERSEUS)Primary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000645-14-HUGenzyme Corporation1,320
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-FIGenzyme Corporation1,700
进行中（未招募）
3 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168Secondary Progressive Multiple SclerosisJPRN-jRCT2031200240Tanaka Tomoyuki1,290
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-GBGenzyme Corporation1,700